Beijing Diagreat Biotechnology

Executive Summary

Beijing Diagreat Biotechnology is a private Chinese diagnostics company specializing in rapid test kits for infectious diseases such as HIV, hepatitis, and sexually transmitted infections. Founded in 2009 and based in Beijing, the company employs 50–200 staff and operates at a commercial stage, serving public health programs and clinical markets. Its product portfolio leverages immunochromatographic and molecular techniques, positioning it as a key player in China's diagnostic ecosystem. Despite a competitive landscape dominated by global and local players, Diagreat's focus on cost-effective, rapid solutions aligns with growing demand for decentralized testing in resource-limited settings. The company's established presence in public health procurement channels provides a stable revenue base and potential for expansion into adjacent markets such as tropical diseases or respiratory infections. However, limited publicly available data on financial performance and pipeline granularity constrain precise valuation. The company's private status and lack of disclosed funding rounds suggest a lean operational model, which may limit scalability but also reduce dilution risk. Overall, Diagreat represents a modest opportunity in the infectious disease diagnostics space, with upside contingent on product innovation and market access.

Upcoming Catalysts (preview)

• Q4 2026Regulatory approval for expanded hepatitis B surface antigen rapid test75% success
• Q3 2026Government procurement contract renewal for HIV rapid test kits80% success
• Q2 2027Launch of multiplex respiratory panel rapid test60% success